This review evaluates the impacts of SGLT2-I, GLP1-RA, and DDP4-I subclasses and classes in comparison to other AHG active comparators and placebo on the risk of non-fatal and fatal ischemic and hemorrhagic stroke in people with T2DM regardless of their risk for either CVD or CKD. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.